Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque 
Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials 
Neil J Korman,1 Kim Papp,2 Jerry Bagel,3 Peter Foley,4 Akimichi Morita,5 Subhashis Banerjee,6 Elizabeth Colston,6 Tao Wang,6 John Throup,6 Diamant Thaçi7
1Case Western Reserve University and University Hospitals, Cleveland, OH, USA; 2Clinical Research and Probity Medical Research, Waterloo, ON, Canada; 3Windsor Dermatology, East Windsor, NJ, USA; 4Skin Health Institute, Carlton, VIC, Australia; 5Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan; 6Bristol Myers Squibb, Princeton, NJ, USA;  
7University of Lübeck, Lübeck, Germany

Introduction
• Deucravacitinib 

 — Novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of 
action distinct from Janus kinase (JAK) 1/2/3 inhibitors1

• Binds to the TYK2 regulatory domain with high selectivity and inhibits TYK2 via 
an allosteric mechanism (Figure 1)1

 — ≥100-fold greater selectivity for TYK2 vs JAK 1/3 and ≥2000-fold greater 
selectivity for TYK2 vs JAK 21,2

• Inhibits TYK2-mediated signaling of cytokines involved in psoriasis pathogenesis 
(eg, interleukin 23 [IL-23], IL-12, and Type I interferons)1

 — Previously demonstrated good efficacy and tolerability in Phase 2 trials in moderate 
to severe plaque psoriasis3 and in active psoriatic arthritis4

Figure 1. Mechanism of action of deucravacitinib

Deucravacitinib
(allosteric inhibitor)

Regulatory
domain

Catalytic
domain

ATP-binding
active site (other kinase inhibitors)

TYK2
ATP, adenosine triphosphate; TYK2, tyrosine kinase 2.

Objective
• To assess the onset of action of deucravacitinib using data from the Phase 3 POETYK 

PSO-1 and PSO-2 trials

Methods
Study designs
• POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) were double-blind, placebo-

controlled, 52-week trials that randomized patients with moderate to severe plaque 
psoriasis (body surface area [BSA] involvement ≥10%, Psoriasis Area and Severity Index [PASI] 
≥12, static Physician’s Global Assessment [sPGA] score ≥3) 1:2:1 to placebo, deucravacitinib  
6 mg once daily, or apremilast 30 mg twice daily (Figure 2)

 — Patients were stratified by geographic region, body weight, and prior biologic use
 — Patients receiving placebo switched to deucravacitinib at Week 16 and patients 

receiving apremilast failing to meet study-specific efficacy thresholds (≥50% 
reduction from baseline in PASI [PASI 50] score in PSO-1, ≥75% reduction from 
baseline in PASI [PASI 75] score in PSO-2) switched to deucravacitinib at Week 24

• Coprimary endpoints were the proportion of patients who achieved PASI 75 and sPGA 
score of 0 or 1 (0/1) responses vs placebo at Week 16

Figure 2. Study designs
POETYK PSO-1 

(N=666)
POETYK PSO-2 

(N=1020)

Deucravacitinib 6 mg QDPlacebo (n=166)

Deucravacitinib 6 mg QD<PASI 50

Apremilast 30 mg BIDPASI 50

Titrate*1
:2

:1
 R

an
d
om

iz
at

io
n

Weeks 16 24 520

Deucravacitinib 6 mg QDPlacebo (n=255)

Deucravacitinib 6 mg QD 
(n=511)

Deucravacitinib 6 mg QD<PASI 75

Deucravacitinib 6 mg QD<PASI 75

Deucravacitinib 6 mg QD

Deucravacitinib 6 mg QD 

Placebob

PASI 75

Apremilast 30 mg BIDa (n=254)

PASI 751
:2

:1
 R

an
d
om

iz
at

io
n

Weeks 16 24 520

1:1

Deucravacitinib 6 mg QDPlacebob

Deucravacitinib 6 mg QD (n=332)

Primary
endpoint

Primary
endpoint

Apremilast 30 mg BIDa (n=168)

aApremilast was titrated from 10 mg QD to 30 mg BID over the first 5 days of dosing. bUpon relapse (≥50% loss of Week 24 PASI 
percentage improvement from baseline), patients were to be switched to deucravacitinib 6 mg QD. BID, twice daily; PASI 50, 
≥50% reduction from baseline in Psoriasis Area and Severity Index; PASI 75, ≥75% reduction from baseline in PASI; QD, once daily.

Efficacy analyses
• Onset of action of deucravacitinib was evaluated by:

 — Determining mean change from baseline or percentage change from baseline, 
adjusted for baseline covariates, in continuous objective and patient-reported 
efficacy outcomes that are sensitive to change

 — Endpoints analyzed included PASI, BSA, sPGA×BSA, Psoriasis Symptoms and Signs 
Diary (PSSD) symptom score, and Dermatology Life Quality Index (DLQI) score at 
Weeks 1, 2, 4, 8, 12, and 16 

• Proportions of patients achieving PASI 75 response, ≥90% reduction from baseline in PASI 
(PASI 90) response, sPGA 0/1, and DLQI 0/1 responses at these time points were also 
evaluated

• The analyses primarily focused on the onset of action of deucravacitinib vs placebo to 
help contextualize the outcomes to be expected in clinical practice

Results
Baseline patient demographics and disease characteristics
• Baseline patient demographics and disease characteristics, including PASI, PSSD symptom 

score, DLQI, BSA, and sPGA×BSA, were similar across treatment groups in both trials and 
representative of a population with moderate to severe plaque psoriasis (Table 1)

Table 1. Baseline patient demographics and disease characteristics
POETYK PSO-1 POETYK PSO-2

Placebo
(n=166)

Deucravacitinib
(n=332)

Placebo
(n=255)

Deucravacitinib
(n=511)

Age, y, mean (SD) 47.9 (14.0) 45.9 (13.7) 47.3 (13.6) 46.9 (13.4)
Weight, kg, mean (SD) 89.1 (22.3) 87.9 (21.8) 91.5 (20.2) 92.3 (21.9)
Female, n (%) 53 (31.9) 102 (30.7) 74 (29.0) 175 (34.2)
Race, n (%)

White 128 (77.1) 267 (80.4) 232 (91.0) 474 (92.8)
Asian 34 (20.5) 59 (17.8) 8 (3.1) 24 (4.7)
Other 4 (2.4) 6 (1.8) 15 (5.9) 13 (2.6)

Disease duration, y,  
mean (SD)

17.3 (12.8) 17.1 (12.4) 19.9 (12.8) 19.6 (12.9)

Prior systemic  
treatment use, n (%)

Biologic 63 (38.0) 130 (39.2) 83 (32.5) 165 (32.3)
No prior systemic thera-
py

57 (34.3) 132 (39.8) 116 (45.5) 237 (46.4)

sPGA, n (%)
3 = moderate 128 (77.1) 257 (77.4) 217 (85.1) 408 (79.8)
4 = severe 37 (22.3) 75 (22.6) 38 (14.9) 103 (20.2)

PASI, mean (SD) 20.7 (8.0) 21.8 (8.6) 21.1 (9.0) 20.7 (7.5)
BSA, %, mean (SD) 25.3 (16.9) 26.6 (15.9) 25.3 (15.7) 26.3 (15.8)
sPGAxBSA, mean (SD) 82.1 (57.3) 86.9 (56.1) 81.1 (56.3) 85.0 (54.6)
PSSD symptom score,a 
mean (SD)

51.4 (26.8) 51.7 (25.2) 50.1 (24.8) 52.3 (26.3)

DLQI, mean (SD) 11.4 (6.6) 12.0 (6.7) 11.8 (6.8) 11.8 (6.5)
aPSSD symptom score is the average severity of 5 symptoms (itch, pain, burning, stinging, and skin tightness) over the 
previous 24 h scored on a scale ranging from 0 (absent) to 100 (worst). BSA, body surface area; DLQI, Dermatology Life 
Quality Index; PASI, Psoriasis Area and Severity Index; PSSD, Psoriasis Symptoms and Signs Diary; sPGA, static Physician’s 
Global Assessment.

Efficacy 
• Deucravacitinib treatment was associated with significantly larger mean changes from 

baseline in PASI vs placebo as early as Week 1 in both trials (P<0.0001; Figure 3)
• Significantly larger mean percentage changes from baseline in PASI were seen in the 

deucravacitinib group vs the placebo group as early as Week 1 in both trials (P<0.001; 
Figure 4)

 — Approximately 40% improvement was seen by Week 4 in the deucravacitinib group in 
both trials

Figure 3. Improvements in mean PASI score over 16 weeks

POETYK PSO-1 POETYK PSO-2

Placebo
(n=166)

Deucravacitinib
(n=332)

Placebo
(n=255)

Deucravacitinib
(n=511)

Baseline PASI, mean (SD) 20.7 (8.0) 21.8 (8.6) 21.1 (9.0) 20.7 (7.5)

Deucravacitinib 6 mg QDPlacebo

-16

-14

-12
-10

-8

-6
-4

-2

0
0 4 8 12 16

Weeks

-16

-14

-12

-10
-8

-6

-4

-2
0

0 4 8 12 16
Weeks

4.4

14.0*

*

*

*

*

*

4.2

14.1*

*

*

*

*

*

1 2 1 2

A
d
ju

st
e
d
 m

e
an

 (
SE

)
ch

an
ge

 f
ro

m
 b

as
e
li
n
e
 P

A
SI

A
d
j u

st
e
d
 m

e
an

 (
SE

)
ch

an
ge

 f
ro

m
 b

as
e
li
n
e
 P

A
SI

POETYK PSO-1 POETYK PSO-2

*P<0.0001 vs placebo. Modified baseline observation carried forward was used to impute missing data. PASI, Psoriasis Area 
and Severity Index; QD, once daily.

Figure 4. Percentage improvements in mean PASI score over 16 weeks

POETYK PSO-1 POETYK PSO-2

Placebo
(n=166)

Deucravacitinib
(n=332)

Placebo
(n=255)

Deucravacitinib
(n=511)

Baseline PASI, mean (SD) 20.7 (8.0) 21.8 (8.6) 21.1 (9.0) 20.7 (7.5)

Deucravacitinib 6 mg QDPlacebo

A
d
ju

st
e
d
 m

e
an

 (
SE

) 
%

 c
h
an

ge
fr

o
m

 b
as

e
li
n
e
 P

A
SI

A
d
ju

st
e
d
 m

e
an

 (
SE

) 
%

 c
h
an

ge
fr

o
m

 b
as

e
li
n
e
 P

A
SI

-80

-60

-40

-20

0
0 4 8 12 16

-80

-60

-40

-20

0
0 4 8 12 16

19.5%

66.5%†

†

*

†

†

†

21.0%

68.1%†

†

†

†

†

†

1 2 1 2

25.7%

42.8%

25.9%

39.6%

WeeksWeeks
POETYK PSO-1 POETYK PSO-2

*P<0.001 vs placebo. †P<0.0001 vs placebo. Modified baseline observation carried forward was used to impute missing data.  
PASI, Psoriasis Area and Severity Index; QD, once daily.

• Significantly larger mean changes from baseline in BSA percentage involvement were 
observed in the deucravacitinib group vs the placebo group by Week 2 (P<0.01; Figure 5)

• Treatment with deucravacitinib resulted in significantly larger mean changes from 
baseline vs placebo in sPGA×BSA by Week 1 in both trials (P<0.01; Figure 6)

Figure 5. Improvements in BSA involvement over 16 weeks

POETYK PSO-1 POETYK PSO-2

Placebo
(n=166)

Deucravacitinib
(n=332)

Placebo
(n=255)

Deucravacitinib
(n=511)

Baseline BSA, %, mean (SD) 25.3 (16.9) 26.6 (15.9) 25.3 (15.7) 26.3 (15.8)

Deucravacitinib 6 mg QDPlacebo

-18
-16
-14
-12
-10
-8
-6
-4
-2
0

0 4 8 12 16

-18
-16
-14
-12
-10
-8
-6
-4
-2
0

0 4 8 12 16

2.5

14.9

*

†

†

†

3.1

16.6
†

†

*

†

A
d
ju

st
e
d
 m

e
an

 (
SE

) 
ch

an
ge

fr
om

 b
as

e
li
n
e
 %

 B
SA

A
d
ju

st
e
d
 m

e
an

 (
SE

) 
ch

an
ge

fr
om

 b
as

e
li
n
e
 %

 B
SA

1 2 1 2
WeeksWeeks

POETYK PSO-1 POETYK PSO-2

*P<0.01 vs placebo. †P<0.0001 vs placebo. Modified baseline observation carried forward was used to impute missing data. 
BSA, body surface area; QD, once daily.

Figure 6. Improvements in sPGA×BSA over 16 weeks

1 2 1 2

-80

-60

-40

-20

0
0 4 8 12 16

-80

-60

-40

-20

0
0 4 8 12 16

59.5

16.6

59.2

14.4
*

†

†

†

†

*

†

†

†

†

A
d
ju

st
e
d
 m

e
an

 (
SE

) 
ch

an
ge

fr
o
m

 b
as

e
li
n
e
 s

P
G

A
B
SA

A
d
ju

st
e
d
 m

e
an

 (
SE

) 
ch

an
ge

fr
o
m

 b
as

e
li
n
e
 s

P
G

A
B
SA

Deucravacitinib 6 mg QDPlacebo

POETYK PSO-1 POETYK PSO-2

Placebo
(n=166)

Deucravacitinib
(n=332)

Placebo
(n=255)

Deucravacitinib
(n=511)

Baseline sPGA BSA, mean (SD) 82.1 (57.3) 86.9 (56.1) 81.1 (56.3) 85.0 (54.6)

WeeksWeeks
POETYK PSO-1 POETYK PSO-2

*P<0.01 vs placebo. †P<0.0001 vs placebo. Modified baseline observation carried forward was used to impute missing data. 
BSA, body surface area; QD, once daily; sPGA, static Physician’s Global Assessment.

• Deucravacitinib-treated individuals experienced significantly larger mean changes from 
baseline in PSSD symptom score vs placebo by Week 2 in PSO-1 and as early as Week 1 in 
PSO-2 (P<0.01 for both; Figure 7)

Figure 7. Improvements in PSSD symptom score over 16 weeks

15

Deucravacitinib 6 mg QDPlacebo

POETYK PSO-1 POETYK PSO-2

Placebo
(n=166)

Deucravacitinib
(n=332)

Placebo
(n=255)

Deucravacitinib
(n=511)

Baseline PSSD, mean (SD) 51.4 (26.8) 51.7 (25.2) 50.1 (24.8) 52.3 (26.3)

-30

-20

-10

0
0 4 8 12 16

*

†

†

†

†

-30

-20

-10

0
0 4 8 12 16

*

1 2 1 2

A
d
ju

st
e
d
 m

e
an

 (
SE

) 
ch

an
ge

fr
o
m

 b
as

e
li
n
e
 P

SS
D

A
d
ju

st
e
d
 m

e
an

 (
SE

) 
ch

an
ge

fr
o
m

 b
as

e
li
n
e
 P

SS
D

3.6

26.7 28.3

†

†

†

4.7

Weeks
8

Weeks
POETYK PSO-1 POETYK PSO-2

*P<0.01 vs placebo. †P<0.0001 vs placebo. Modified baseline observation carried forward was used to impute missing data.  
PSSD, Psoriasis Symptoms and Signs Diary; QD, once daily.

• Significantly larger mean changes from baseline in DLQI were seen with the 
deucravacitinib group vs the placebo group by Week 1 (P<0.05) in both trials (Figure 8)

Figure 8. Improvements in DLQI score over 16 weeks

Deucravacitinib 6 mg QDPlacebo

POETYK PSO-1 POETYK PSO-2

Placebo
(n=166)

Deucravacitinib
(n=332)

Placebo
(n=255)

Deucravacitinib
(n=511)

Baseline DLQI, mean (SD) 11.4 (6.6) 12.0 (6.7) 11.8 (6.8) 11.8 (6.5)

1 2 1 2

-10

-8

-6

-4

-2

0
0 4 8 12 16

-10

-8

-6

-4

-2

0
0 4 8 12 16

3.0

7.6
†

*

†

†

†

3.3

8.5

*
†

†

†

†

A
d
ju

st
e
d
 m

e
an

 (
SE

) 
ch

an
ge

fr
o
m

 b
as

e
li
n
e
 D

LQ
I

A
d
ju

st
e
d
 m

e
an

 (
SE

) 
ch

an
ge

fr
o
m

 b
as

e
li
n
e
 D

LQ
I

WeeksWeeks
POETYK PSO-1 POETYK PSO-2

*P<0.05 vs placebo. †P<0.0001 vs placebo. Modified baseline observation carried forward was used to impute missing data.  
DLQI, Dermatology Life Quality Index; QD, once daily.

• In both trials, significantly higher proportions of patients achieved PASI 75 responses in 
the deucravacitinib group vs the placebo group by Week 4 (P<0.001; Figure 9)

Figure 9. Achievement of PASI 75 response over 16 weeks

Deucravacitinib 6 mg QDPlacebo

0

20

40

60

80

100

0 4 8 12 16

58.4%†

12.7%

0

20

40

60

80

100

0 4 8 12 16

†

†
53.0%†

9.4%

21

POETYK PSO-1 POETYK PSO-2

Weeks Weeks

P
A

SI
 7

5
 r

e
sp

o
n
se

 r
at

e
 (

9
5
%

 C
I)

, 
%

P
A

SI
 7

5
 r

e
sp

o
n
se

 r
at

e
 (

9
5
%

 C
I)

, 
%

1 2

*

†

†

*

*P<0.001 vs placebo. †P<0.0001 vs placebo. Modified baseline observation carried forward was used to impute missing data.  
PASI 75, ≥75% reduction from baseline in Psoriasis Area and Severity Index; QD, once daily.

• The proportion of patients achieving sPGA 0/1 response was significantly higher in the 
deucravacitinib group vs the placebo group by Week 4 in PSO-1 (P<0.0001) and by Week 
2 in PSO-2 (P<0.001; Figure 10)

Figure 10. Achievement of sPGA 0/1 responsea over 16 weeks
POETYK PSO-1 POETYK PSO-2

Deucravacitinib 6 mg QDPlacebo

0

20

40

60

80

100

0 4 8 12 16
0

20

40

60

80

100

0 4 8 12 16

†

†

†

sP
G

A
 0

/1
 r

e
sp

o
n
se

 r
at

e
 (

9
5
%

 C
I)

, 
%

53.6%†

7.2%

49.5%†

8.6%

Weeks Weeks

*

†

† 

† 

1 2 21

sP
G

A
 0

/1
 r

e
sp

o
n
se

 r
at

e
 (

9
5
%

 C
I)

, 
%

aResponse defined as sPGA score of 0 or 1 with ≥2-point improvement from baseline. *P<0.001 vs placebo. †P<0.0001 vs 
placebo. Nonresponder imputation was used to impute missing data. sPGA 0/1, static Physician’s Global Assessment score 
of 0 or 1; QD, once daily.

• PASI 90 response rates were significantly higher in the deucravacitinib group vs the 
placebo group by Week 8 in PSO-1 (P<0.0001) and Week 4 in PSO-2 (P<0.05; Figure 11)

Figure 11. Achievement of PASI 90 response over 16 weeks
POETYK PSO-1 POETYK PSO-2

Deucravacitinib 6 mg QDPlacebo

0

20

40

60

80

100

0 4 8 12 16

35.5%†

4.2%

0

20

40

60

80

100

0 4 8 12 16

†

†
27.0%†

2.7%

Weeks Weeks

P
A

SI
 9

0
 r

e
sp

o
n
se

 r
at

e
 (

9
5
%

 C
I)

, 
%

P
A

SI
 9

0
 r

e
sp

o
n
se

 r
at

e
 (

9
5
%

 C
I)

, 
%

†

†

*

1 2 21

*P<0.05 vs placebo. †P<0.0001 vs placebo. Nonresponder imputation was used to impute missing data. PASI 90, ≥90% 
reduction from baseline in Psoriasis Area and Severity Index; QD, once daily.

• The proportion of patients achieving DLQI 0/1 response was significantly higher in the 
deucravacitinib group vs the placebo group by Week 2 in PSO-1 and by Week 4 in PSO-2 
(Figure 12)

Figure 12. DLQI 0/1 responsea through 16 weeks
POETYK PSO-1 POETYK PSO-2

Deucravacitinib 6 mg QDPlacebo

0

20

40

60

80

100

0 4 8 12 161 2

41.0%†

10.6%

0

20

40

60

80

100

0 4 8 12 161 2

37.6%†

9.8%

D
LQ

I 
0
/1

 r
e
sp

o
n
se

 r
at

e
 (

9
5
%

 C
I)

, 
%

D
LQ

I 
0
/1

 r
e
sp

o
n
se

 r
at

e
 (

9
5
%

 C
I)

, 
%

Weeks Weeks

*
*

†

†

*

†

†

aAmong patients with baseline DLQI score ≥2. *P<0.05 vs placebo. †P<0.0001 vs placebo. Nonresponder imputation was used 
to impute missing data. DLQI 0/1, Dermatology Life Quality Index score of 0 or 1; QD, once daily.

• In both trials, the superiority of deucravacitinib vs apremilast was observed as early as 
Week 4 for change from baseline in PASI (Figure 13) and all other endpoints assessed 
(data not shown)

Figure 13. Improvements from baseline PASI score over 16 weeks

POETYK PSO-1 POETYK PSO-2

Placebo
(n=166)

Deucravacitinib
(n=332)

Apremilast
(n=168)

Placebo
(n=255)

Deucravacitinib
(n=511)

Apremilast
(n=168)

Baseline PASI score, mean (SD) 20.7 (8.0) 21.8 (8.6) 21.4 (9.0) 21.1 (9.0) 20.7 (7.5) 21.6 (8.4)

Deucravacitinib 6 mg QDPlacebo Apremilast 30 mg BID

-18
-16
-14
-12
-10
-8
-6
-4
-2
0

0 4 8 12 16
Weeks

-18
-16
-14
-12
-10
-8
-6
-4
-2
0

0 4 8 12 16
Weeks

4.4

14.0*†

†

†

†

4.2

14.1*†

†

†

*†
9.6

10.8

POETYK PSO-1 POETYK PSO-2

1 2 1 2

*†

*†

*†

*†A
d
ju

st
e
d
 m

e
an

 c
h
an

ge
fr

om
 b

as
e
li
n
e
 P

A
SI

 s
co

re

A
d
ju

st
e
d
 m

e
an

 c
h
an

ge
fr

om
 b

as
e
li
n
e
 P

A
SI

 s
co

re

*P≤0.0019 vs apremilast. †P<0.0001 vs placebo. Modified baseline observation carried forward was used to impute missing 
data. BID, twice daily; PASI, Psoriasis Area and Severity Index; QD, once daily. 

Conclusions
• In the Phase 3 POETYK PSO-1 and PSO-2 trials, oral deucravacitinib had a rapid 

onset of action and improved objective and patient-reported efficacy outcomes 
compared with placebo as early as Week 1

• These findings suggest that deucravacitinib treatment provides rapid relief of signs 
and symptoms in patients with moderate to severe plaque psoriasis

• Taken together with the primary results from the Phase 3 POETYK trials, 
deucravacitinib, a once-daily, oral, selective TYK2 inhibitor, has the potential to 
become a valuable treatment of choice and new standard of care for patients with 
moderate to severe plaque psoriasis 

References
1. Burke JR et al. Sci Transl Med 2019;11:1-16. 
2. Wrobleski ST et al. J Med Chem 2019;62:8973-8995. 
3. Papp K et al. N Engl J Med 2018;379:1313-1321. 
4.  Mease PJ et al. Presented at the Annual Scientific Meeting of the American College of Rheumatology; November 5-9, 2020.

Acknowledgments
• These clinical trials were sponsored by Bristol Myers Squibb. Professional medical writing and editorial assistance were provided 

by Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and were funded by Bristol Myers Squibb.

Relationships and Activities
• NJK: Advisory board, consulting fees: AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo 

Pharma, Novartis, Principia, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB; Grant support/principal investigator: 
AbbVie, Amgen, Argenx, Bristol Myers Squibb, Celgene, Chemocentryx, Eli Lilly, Galderma, Kyowa Hakko Kirin, Leo Pharma, 
Menlo, Principia, Prothena, Rhizen, Syntimmune, Trevi, and Xbiotech; Speaker: AbbVie, Eli Lilly, Janssen, Novartis, 
Regeneron, and Sanofi Genzyme 

• KP: Speakers bureau: AbbVie, Amgen, Astellas, Celgene, Eli Lilly, Galderma, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck 
Sharp & Dohme, Novartis, Pfizer, and Valeant; Grant/research support: AbbVie, Akros, Allergan, Amgen, Anacor, Arcutis, 
AstraZeneca, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, 
Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Leo Pharma, MedImmune, Meiji Seika Pharma, Merck 
Serono, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, and Valeant; Consultant: AbbVie, Akros, Amgen, 
Arcutis, Astellas, AstraZeneca, Baxalta, Baxter, Boehringer Ingelheim, Bristol Myers Squibb, CanFite, Celgene, Coherus, 
Dermira, Dow Pharma, Eli Lilly, Forward Pharma, Galderma, Genentech, Janssen, Kyowa Hakko Kirin, Leo Pharma, Meiji Seika 
Pharma, Merck Serono, Merck Sharp & Dohme, Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, 
Takeda, UCB, and Valeant; Honoraria: AbbVie, Akros, Amgen, Baxter, Boehringer Ingelheim, Celgene, Coherus, Eli Lilly, 
Forward Pharma, Galderma, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Merck Serono, Merck Sharp & Dohme, Novartis, 
Pfizer, Takeda, UCB, and Valeant; Scientific officer/steering committee/advisory board: AbbVie, Akros, Amgen, Anacor, 
Astellas, Baxter, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dow Pharma, Eli Lilly, Galderma, Janssen, Kyowa 
Hakko Kirin, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Sanofi Genzyme, and Valeant

• JB: Research funds payable to the Psoriasis Treatment Center of New Jersey: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, 
Bristol Myers Squibb, Celgene, CorEvitas’ Psoriasis Registry, Dermavant, Dermira/UCB, Eli Lilly, Glenmark, Janssen Biotech, 
Kadmon, Leo Pharma, Lycera, Menlo, Novartis, Pfizer, Regeneron, Sun Pharma, Taro, and Valeant; Consultant: AbbVie, Amgen, 
Celgene, Eli Lilly, Janssen Biotech, Novartis, Sun Pharma, and Valeant; Speaker: AbbVie, Celgene, Eli Lilly, Janssen Biotech, 
and Novartis

• PF: Grant support: AbbVie, Amgen, Celgene, Janssen, Leo Pharma, Lilly, Merck, Novartis, Pfizer, Sanofi, and Sun Pharma; 
Investigator: AbbVie, Amgen, Arcutis, Aslan, AstraZeneca, Boehringer Ingelheim, Botanix, Bristol Myers Squibb, Celgene, 
Celtaxsys, CSL, Cutanea, Dermira, Galderma, Genentech, GlaxoSmithKline, Hexima, Janssen, Leo Pharma, Lilly, Merck, 
Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi, Sun Pharma, UCB, and Valeant; Advisory board: AbbVie, Amgen, 
Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galderma, GlaxoSmithKline, Janssen, Leo Pharma, Lilly, Merck, 
Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and Valeant; Consultant: Bristol Myers Squibb, Galderma, Janssen, Leo Pharma, 
Lilly, Novartis, Pfizer, Roche, and UCB; Travel grants: AbbVie, Galderma, Janssen, Leo Pharma, Lilly, Merck, Novartis, Pfizer, 
Roche, Sun Pharma, and Sanofi; Speaker for or honoraria from: AbbVie, Amgen, Celgene, Galderma, GlaxoSmithKline, 
Janssen, Leo Pharma, Lilly, Merck, Novartis, Pfizer, Roche, and Valeant 

• AM: Grant/research support, consultant, speakers bureau: AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, 
Eli Lilly, Janssen, Kyowa Hakko Kirin, Leo Pharma, Maruho, Mitsubishi Tanabe, Nichi-Iko, Nippon Kayaku, Novartis, Pfizer, Sun 
Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, UCB, and Ushio 

• SB, EC, TW, and JT: Employees and shareholders: Bristol Myers Squibb
• DT: Research support/principal investigator (clinical trials): AbbVie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, 

Celgene, Dermira, DS Pharma, Eli Lilly, Galapagos, Galderma, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, Regeneron, Roche, 
Sandoz-Hexal, Sanofi, and UCB; Consultant: AbbVie, Almirall, Amgen, Janssen, Leo Pharma, Novartis, Roche-Posay, Sandoz-
Hexal, Sanofi, and UCB; Scientific advisory board: AbbVie, Amgen, Eli Lilly, Galapagos, Janssen-Cilag, Leo Pharma, Morphosis, 
Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, and UCB 

Presented at the Fall Clinical Dermatology Conference®; October 21—24, 2021; Las Vegas, NV, and Virtual
This is an encore of the 2021 EADV 30th Congress poster and the 2021 NPF Research Symposium poster

This poster may not be reproduced without written permission from the authors.Email for Neil J Korman, MD, PhD: Neil.Korman@UHhospitals.org